GlassScriptPhysician profile
Eleni Moraites
NPI 1417022161
$4,521.23
in general payments reported to CMS, 2019-2025
26 companies · $546 in 2025
The $546 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $95.96 · 2021: $249 · 2022: $871 · 2023: $1,243 · 2024: $962 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.89 |
| Education | $436.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.40 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $856.46 | 2019-2025 | |
| Janssen Biotech, INC. | $717.58 | 2020-2025 | Tremfya, Remicade, Simponi |
| Amgen INC. | $398.91 | 2019-2024 | Otezla |
| Ucb, INC. | $272.85 | 2019-2023 | Cimzia |
| Dermavant Sciences, INC. | $209.40 | 2023-2024 | Vtama |
| Lilly USA, LLC | $194.41 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $175.01 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Genzyme Corporation | $110.13 | 2019-2023 | |
| Leo Pharma INC. | $87.72 | 2022-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $82.44 | 2023-2024 | Sotyktu |
| Pfizer INC. | $76.35 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $64.56 | 2019-2022 | |
| Incyte Corporation | $58.83 | 2023-2024 | Opzelura |
| Organon LLC | $47.73 | 2024-2025 | Hadlima, Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $43.45 | 2019 | |
| Genentech USA, INC. | $43.20 | 2019-2022 | |
| Galderma Laboratories, L.P. | $35.74 | 2024 | |
| Merz Pharmaceuticals, LLC | $29.74 | 2024 | Xeomin |
| Smith+Nephew, INC. | $28.87 | 2020 | |
| Botanix Sb INC | $24.80 | 2025 | Sofdra |
| Celgene Corporation | $22.18 | 2019 | |
| Organogenesis INC. | $19.34 | 2025 | Cygnus Dual |
| Verrica Pharmaceuticals INC. | $19.01 | 2024 | Ycanth |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $12.12 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleni Moraites listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.